The High Court held that the Tribunal misapplied the law on presumptions under Sections 132(4A) and 292C by wrongly shifting the burden to the Revenue. The matter was remanded for fresh ...

Immatics has innovative TCR therapies, strong cash position, and expanding clinical pipeline targeting solid tumors. Read for ...

The guide explains that stock audits assess the quality, ownership, and value of bank security, with Drawing Power as the key ...

The biggest delinquent account is an entity listed as “Shareholders Mythics Emergent Group,” which owes more than $20 million ...

Q4 2025 Earnings Call Transcript December 17, 2025 Veru Inc. beats earnings expectations. Reported EPS is $0.05, expectations ...

Repare Therapeutics Inc. ("Repare" or the "Company") , a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's ...

Veru Inc (($VERU)) has held its Q4 earnings call. Read on for the main highlights of the call. Veru Inc. Balances Clinical Breakthroughs With ...

Volato Group, Inc. (the "Company" or "Volato") , today announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against ...

Series D & J—with strong dividend coverage and moderate redemption risk. Read my analysis of SCHW and its preferreds.

HHS Secretary Robert F. Kennedy Jr.s CDC just funneled a $1.6 million dollar grant to researchers to carry out an unethical and scientifically unjustified randomized clinical trial of the birth dose o ...

BOSTON & MONTREAL, December 22, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, ...

Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling WorkTAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology ...